CCL2 and Sarcopenia: Cohort, UK Biobank and GTEx Evidence
In 323 older adults, circulating CCL2 was higher with sarcopenia, weak muscle strength or poor physical performance; UK Biobank data confirmed the link, while genetic and tissue analyses suggested it may not be causal. [1]
Automatic summary · not editorially reviewed
The key findings
The study examined the association between circulating CCL2 and sarcopenia-related parameters in 323 community-dwelling older adults. [1]
Serum CCL2 levels were significantly higher in participants with sarcopenia, weak muscle strength or poor physical performance. [1]
The authors suggest elevated circulating CCL2 in sarcopenia may reflect a compensatory response rather than a direct pathogenic driver. [1]
The source at a glance
- Study type / format
- Cohort study with UK Biobank validation, GTEx tissue analysis and Mendelian randomization (abstract only).
- Population / context
- 323 community-dwelling older adults; UK Biobank data from 54,219 people; GTEx tissue data from 818 people.
- Summary based on
- Study abstract
- Original publication
- October 15, 2026
Does circulating CCL2 track with sarcopenia in older adults?
Chronic inflammation is considered a feature of aging, but the role of the inflammatory mediator CCL2 in skeletal muscle health is unclear. CCL2 is often seen as harmful in aging, yet it is also needed for muscle formation. The researchers asked how CCL2 relates to human muscle metabolism, using clinical, protein, gene-activity and genetic data together.
Supporting source [1]
323 older adults, UK Biobank and tissue data compared
The team combined several approaches. They examined the association between circulating CCL2 and sarcopenia-related parameters in 323 community-dwelling older adults and checked it in UK Biobank data from 54,219 people. Tissue-level analysis used GTEx gene-activity data from 818 people, and a genetic method (Mendelian randomization) was used to assess causality.
Supporting source [1]
Higher CCL2 with sarcopenia, but causality questioned
In the cohort, serum CCL2 was significantly higher in participants with sarcopenia, weak muscle strength or poor physical performance. The abstract does not report the direction or size of the genetic and tissue results. The authors conclude that the differing findings raise the possibility that elevated circulating CCL2 in sarcopenia reflects a compensatory response to muscle deterioration rather than a direct cause, and they call for further mechanistic validation.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract gives no effect sizes, no direction or size of the genetic and tissue results, and no details on follow-up or how sarcopenia was defined. Associations are not causes.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Kwak MK, Kim SJ, Park SJ, Dao T, Baek JY, Ryu D, Kim JY, Jang GY, Lee E, Sakong H, Lee Y, Hong EG, Jo Y, Kim BJ. · europepmc.org · October 15, 2026